The Technical Analyst
Quest Diagnostics Inc [DGX]
Exchange: NYSE Sector: Healthcare Industry: Diagnostics & Research
Quest Diagnostics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.10% $137.64
America/New_York / 9 mai 2024 @ 13:02
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 15 291 mill |
| EPS: | 7.44 |
| P/E: | 18.50 |
| Earnings Date: | Jul 24, 2024 |
| SharesOutstanding: | 111.09 mill |
| Avg Daily Volume: | 0.990 mill |
| RATING 2024-05-09 |
|---|
| A+ |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Buy | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Buy | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.20x |
| Company: PE 18.50 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.17x |
| Company: PE 18.50 | industry: PE 109.92 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$202.49 (47.12%) $64.85 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 135.14 - 139.69 ( +/- 1.66%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-29 | Kuppusamy Karthik | Sell | 1 760 | Common Stock |
| 2024-04-22 | Gregg Vicky B | Buy | 81 | Common Stock |
| 2024-04-22 | Kuppusamy Karthik | Buy | 45 | Common Stock |
| 2024-04-22 | Plewman Patrick | Buy | 69 | Common Stock |
| 2024-04-22 | Samad Sam | Buy | 24 | Common Stock |
| INSIDER POWER |
|---|
| 70.86 |
| Last 98 transactions |
| Buy: 293 398 | Sell: 48 907 |
Forecast:
14:41 - $137.41
Live Trading Signals (every 1 min)
Forecast
1: 13:11 - $137.50
Forecast 2: 14:01 - $137.44
Forecast 3: 14:41 - $137.41
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $137.64 (1.10% ) |
| Volume | 0.144 mill |
| Avg. Vol. | 0.990 mill |
| % of Avg. Vol | 14.52 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For DGX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
DGX
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Latest Press Releases
2024-05-07 16:50:00 - Press Release
Quest Diagnostics To Speak At The 2024 Leerink Partners Healthcare Crossroads Conference
Secaucus, n.j. , may 7, 2024 /prnewswire/ -- quest diagnostics incorporated (nyse: dgx), a leader in diagnostic information services, announced that jim davis, chairman, ceo and president, will speak on the company's strategy, performance and the latest market developments and trends during a fireside chat at the 2024 leerink partners healthcare crossroads conference in austin, texas on wednesday, may 29, 2024, at 10:20 a.m.
2024-05-06 09:40:00 - Press Release
Quest Diagnostics Names Murali Balakumar Senior Vice President And Chief Information And Digital Officer
Secaucus, n.j. , may 6, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), a leading provider of diagnostic information services, announced today that murali balakumar, a veteran information technology healthcare business leader, has been named senior vice president and chief information and digital officer (cido).
2024-05-01 06:57:00 - Press Release
Quest Diagnostics To Acquire Pathai Diagnostics To Accelerate Ai And Digital Pathology Adoption In Cancer Diagnosis; Forms Licensing Agreements With Pathai
Transaction is part of wide-ranging collaboration to combine quest's oncology expertise and scale with pathai's ai and digital pathology innovations to speed diagnosis, improve quality and reduce costs secaucus, n.j. and boston , may 1, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, and pathai, a global provider of artificial intelligence-powered technology for pathology, today announced a multi-faceted collaboration designed to accelerate the adoption of digital and ai pathology innovations to improve quality, speed and efficiency in diagnosing cancer and other diseases.
2024-04-23 06:45:00 - Press Release
Quest Diagnostics Reports First Quarter 2024 Financial Results; Raises Guidance For Full Year 2024
First quarter revenues of $2.37 billion, up 1.5% from 2023 first quarter reported diluted earnings per share ("eps") of $1.72, down 3.4% from 2023; and adjusted diluted eps of $2.04, flat with 2023 full year 2024 revenues now expected to be between $9.40 billion and $9.48 billion; reported diluted eps now expected to be between $7.57 and $7.82; and adjusted diluted eps expected to be between $8.72 and $8.97 secaucus, n.j. , april 23, 2024 /prnewswire/ -- quest diagnostics incorporated (nyse: dgx), a leading provider of diagnostic information services, today announced financial results for the first quarter ended march 31, 2024.
2024-04-22 07:53:00 - Press Release
Quest Diagnostics Adds P-tau217 Blood Biomarker Testing To Suite Of Services Designed To Assess Risk And Help Aid Diagnosis Of Alzheimer's Disease
Company's ad-detect™ portfolio offers ab 42/40 and other plasma biomarker testing, alongside traditional cerebrospinal fluid and genetic tests, to provide robust offering in brain health secaucus, n.j. , april 22, 2024 /prnewswire/ -- quest diagnostics (nyse: dgx), a leader in diagnostic information services, today announced the launch of a new blood biomarker test for phosphorylated tau 217, or p-tau217.
Latest News
2024-05-07 12:26:06 - Zacks Investment Research
Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal
Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.
2024-05-02 11:46:06 - Zacks Investment Research
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
2024-05-02 10:05:26 - Zacks Investment Research
Quest Diagnostics (DGX) Inks Deal to Acquire PathAI Diagnostics
Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.
2024-04-29 19:21:00 - Market Watch
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorously opposed by the testing industry.
2024-04-23 10:56:17 - Zacks Investment Research
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
2024-04-23 08:56:04 - Zacks Investment Research
Quest Diagnostics (DGX) Beats Q1 Earnings and Revenue Estimates
Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago.
2024-04-23 08:02:04 - Reuters
Quest Diagnostics raises 2024 profit and revenue forecast on strong demand
Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.
2024-04-16 11:06:58 - Zacks Investment Research
Earnings Preview: Quest Diagnostics (DGX) Q1 Earnings Expected to Decline
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2024-04-15 10:51:09 - Zacks Investment Research
Quest Diagnostics (DGX) to Post Q1 Earnings: What's in Store?
Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.
2024-04-03 12:26:09 - Zacks Investment Research
Quest Diagnostics (DGX) Collaborates With Broad Clinical Labs
Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.